Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
A Phase IIa, Multi-centre, Randomized, Double-Blind, Double-Dummy, Active and Placebo Controlled, parallel Group Study to Assess the Efficacy and Safety of AZD2066 after 6 weeks of treatment in Patients with Major Depressive Disorder - D0475C00020.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Provision of signed, written, and dated Informed Consent
Documented primary clinical diagnosis of Major Depressive Disorder
You may not be if
Patients with a secondary psychiatric disorder including bipolar disorder, psychotic disorders (i.e. schizophrenia, schizoaffective disorder, depression with psychotic features), GAD and social anxiety disorder
Patients whose current episode of depression started less than 4 weeks before enrollment
History of inadequate response of antidepressants during current depressive episode
Clareo Health | 6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder
